Longevity-focused biotechnology company Immorta Bio Inc announced on Tuesday the appointment of Dr. Russel Kaufman to its board of directors.

Dr Kaufman is a venture partner at Pappas Capital and president emeritus of The Wistar Institute. He was associated with Duke University for more than 25 years, with multiple professional and administrative appointments including professor of Medicine, chief, division of Medical Oncology and Transplantation, as well as dean of School of Medicine. His corporate experience includes board roles at the CEO Council for Growth in Philadelphia, BioAdvance, Osage Ventures, Militia Hill Ventures, Biorasi, Neuland Pharmaceutical Labs and Credit Suisse (SAB).

Dr Kaufman said: "I had the privilege of serving on the board of Dr Reznik's successful previous company, Biorasi, and I am honoured to collaborate with him and his team on this exciting new venture, Immorta Bio. Having witnessed Dr Reznik's perseverance, talent and executive expertise in translational medicine and clinical trials, I am confident in the potential of this new endeavour. The company's focus on longevity, combined with its cutting-edge technologies in cellular rejuvenation and senolytic immunotherapy, makes this undertaking particularly exciting. I am very impressed by the rapid progress the company has made, advancing from formation to IND filing with the FDA in just one year. While such accelerated growth is exceptional, it is characteristic of Dr Reznik's leadership and the remarkable teams he leads."